Adocia SA (EPA:ADOC)

Market Cap	48.62M -69.1%
Revenue (ttm)	2.98M -76.8%
Net Income	-15.90M
EPS	-0.83
Shares Out	20.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	167,515
Open	2.340
Previous Close	2.360
Day's Range	2.324 - 2.442
52-Week Range	2.010 - 9.760
Beta	0.39
Analysts	Buy
Price Target	9.70 (+299.18%)
Earnings Date	Sep 24, 2026

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. The company’s proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone GLP-1 Amylin, a combination of acting insulin glargine and rapid-acting insulin lispro, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 80
• Stock Exchange: Euronext Paris
• Ticker Symbol: ADOC

Financial Performance

In 2025, Adocia's revenue was 3.85 million, a decrease of -68.26% compared to the previous year's 12.12 million. Losses were -16.59 million, 78.0% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for ADOC stock is "Buy." The 12-month stock price target is €9.70, which is an increase of 299.18% from the latest price.

Price Target

€9.70

(299.18% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error